

<b>Part 1</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application No.	10/564,166
	Filing Date:	July 5, 2004
	First Name Inventor	Valerio Berdini
	Art Unit	1626
	Examiner Name	Stockton, Laura Lynne
	Attorney Docket No.	3073.004A

### U.S. PATENTS

Examiner Initials	Cite No.	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	A1	6696437	B1	2004-02-24	Lubisch et al.	
	A2	5952368	A	1999-09-14	Kertesz et al.	
	A3	6350746	B1	2002-02-26	Buckman et al.	
	A4	7087616	B2	2006-08-08	Fischer et al.	
	A5	6358978		2002-03-19	Ritzeler et al.	

### U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials	Cite No.	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	B1	2004/0048868	A1	2004-03-11	Edwards et al.	
	B2	2003/0207883	A1	2003-11-06	Renhowe et al.	
	B3	2004/0214814	A1	2004-10-28	Bebbington et al.	
	B4	2004/0242559	A1	2004-12-02	Ugolini et al.	
	B5	2007/0021472	A1	2007-01-25	Zhu et al.	
	B6	2004/0082798	A1	2004-04-29	Alonso-Alija et al.	
	B7	2007/0208007	A1	2007-09-06	Saitou et al.	
	B8	2005/0009894	A1	2005-01-13	Babin et al.	
	B9	2008/0132495	A1	2008-06-05	Berdini et al.	

<b>Part 1</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application No.	10/564,166
	Filing Date:	July 5, 2004
	First Name Inventor	Valerio Berdini
	Art Unit	1626
	Examiner Name	Stockton, Laura Lynne
	Attorney Docket No.	3073.004A

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Figures Appear	Translation	
								Yes	No
	C1	2003/035065	WO	A1	2003-05-01	Aventis Pharmaceuticals Inc.			
	C2	2003/004488	WO	A1	2003-01-16	Chiron Corporation			
	C3	2001/079198	WO	A1	2001-10-25	Agouron Pharmaceuticals, Inc.			
	C4	2001/057022	WO	A2	2001-08-09	Vertex Pharmaceuticals Incorporated			
	C5	2005/002576	WO	A2	2005-01-13	Astex Technology Limited			
	C6	2005/005414	WO	A2	2005-01-20	Pharmacia Italia S.P.A.			
	C7	0169051	EP	A2	1986-01-22	Eli Lilly and Company			
	C8	2003/066629	WO	A2	2003-08-14	Vertex Pharmaceuticals Incorporated			
	C9	1999/046244	WO	A1	1999-09-16	Novo Nordisk			
	C10	2005/028624	WO	A2	2005-03-31	Plexxikon, Inc.			
	C11	2001/019798	WO	A2	2001-03-22	Cor Therapeutics, Inc.			
	C12	2001/064642	WO	A2	2001-09-07	Cor Therapeutics, Inc.			
	C13	2001/064643	WO	A2	2001-09-07	Cor Therapeutics, Inc.			
	C14	2001/019788	WO	A2	2001-03-22	Cor Therapeutics, Inc.			
	C15	2002/000651	WO	A2	2002-01-03	Dupont Pharmaceuticals Company			

<b>Part 1</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application No.	10/564,166
	Filing Date:	July 5, 2004
	First Name Inventor	Valerio Berdini
	Art Unit	1626
	Examiner Name	Stockton, Laura Lynne
	Attorney Docket No.	3073.004A

Examiner Initials	Cite No.	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Figures Appear	Translation	
								Yes	No
	C16	2000/039108	WO	A1	2000-07-06	Du Pont Pharmaceuticals Company			
	C17	1264820	EP		2002-12-11	Fujisawa Pharmaceutical Co., Ltd			
	C18	1997/036585	WO	A1	1997-10-09	Merck & Co., Inc.			
	C19	2000/059902	WO	A2	2000-10-12	Du Pont Pharmaceuticals Company			
	C20	1997/012615	WO	A1	1997-04-10	Warner-lambert Company			
	C21	1994/029300	WO	A1	1994-12-22	Rhone Poulenc Agrochimie			
	C22	1999/061426	WO	A1	1999-12-02	Scios, Inc.			
	C23	2002/000647	WO	A1	2002-01-03	Dupont Pharmaceuticals Company			
	C24	2002/000655	WO	A1	2002-01-03	Dupont Pharmaceuticals Company			
	C25	1994/014435	WO	A1	1994-07-07	Rhone Poulenc Rorer Pharmaceuticals Inc.			
	C26	2004/041277	WO	A1	2004-05-21	Merck & Co., Inc.			
	C27	2003/053941	WO	A2	2003-07-03	Bristol-Myers Squibb Company			
	C28	2000/064888	WO	A1	2000-11-02	Aventis Pharmaceuticals Products Inc.			

<b>Part 1</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application No.	10/564,166
	Filing Date:	July 5, 2004
	First Name Inventor	Valerio Berdini
	Art Unit	1626
	Examiner Name	Stockton, Laura Lynne
	Attorney Docket No.	3073.004A

Examiner Initials	Cite No.	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Figures Appear	Translation	
								Yes	No
	C29	1460067	EP		2004-09-22	Takeda Chemical Industries, Ltd.			
	C30	2002/096426	WO	A1	2002-12-05	Bristol-Myers Squibb Company			
	C31	2004/054515	WO	A2	2004-07-01	Smithkline Beecham Corporation			
	C32	2004/050636	WO	A2	2004-06-17	Aventis Pharma Deutschland GMBH			
	C33	2004/056815	WO	A1	2004-07-08	Aventis Pharma Deutschland GMBH			
	C34	2003/044014	WO	A1	2003-05-30	Aventis Pharma Deutschland GMBH			
	C35	2004/052370	WO	A1	2004-06-24	7TM Pharma A/S			
	C36	1996/000218	WO	A1	1996-01-04	Euroceltique, S.A.			
	C37	2000/043384	WO	A1	2000-07-27	Boehringer Ingelheim Pharmaceuticals, Inc.			
	C38	2001/002385	WO	A1	2001-01-11	Aventis Cropscience S.A.			
	C39	2003/006465	WO	A1	2003-01-23	CV Therapeutics, Inc.			
	C40	2003/002566	WO	A1	2003-01-09	CV Therapeutics, Inc.			
	C41	2005/047266	WO	A1	2005-05-26	Lorus Therapeutics Inc.			

<b>Part 1</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application No.	10/564,166
	Filing Date:	July 5, 2004
	First Name Inventor	Valerio Berdini
	Art Unit	1626
	Examiner Name	Stockton, Laura Lynne
	Attorney Docket No.	3073.004A

Examiner Initials	Cite No.	Foreign Document Number <sup>1</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Figures Appear	Translation	
								Yes	No
	C42	2002/072549	WO	A1	2002-09-19	Millennium Pharmaceuticals, Inc.			
	C43	2007/077435	WO	A1	2007-07-12	Astex Therapeutics Limited			
	C44	2008/001115	WO	A2	2008-01-03	Astex Therapeutics Limited			
	C45	2008/001101	WO	A2	2008-01-03	Astex Therapeutics Limited			

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	D	
EXAMINER:		Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP Section 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="http://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3) <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.		